Relacorilant is an investigational drug that blocks the activity of cortisol, a stress hormone, at its receptor. Cortisol receptors are found on many tumours, including a substantial share of ovarian cancers, and researchers have hypothesised that blocking cortisol signalling may make cancer cells more vulnerable to chemotherapy. In plain terms, the drug aims to remove a hormonal signal that may help the tumour survive, so that the accompanying chemotherapy works better.

Earlier-phase studies of this combination had suggested enough promise to justify a larger, phase 3 trial — the final stage of testing typically required before regulators decide whether to approve a new therapy.

Why does "overall survival" matter?

Overall survival — how long patients actually live — is considered the most rigorous endpoint in cancer trials. Many studies instead measure progression-free survival, the time before the disease worsens, which can be measured sooner but does not always translate into longer life. Because ROSELLA reported overall survival as its primary measure, its results carry particular weight for clinicians weighing treatment options.

What are the limitations to keep in mind?

As with any single phase 3 trial, the findings apply specifically to the population studied: patients with platinum-resistant ovarian cancer who met the trial's entry criteria. Results from one trial do not automatically generalise to every patient with the disease, and researchers typically want to see how findings hold up across subgroups and in real-world clinical practice.

Details of the trial — including its exact size, the survival figures for each treatment group, and the safety profile patients experienced — are reported in the full publication in The Lancet. Readers looking for those specifics should consult the journal article directly.

What happens next?

Phase 3 results feed into regulatory decisions. Depending on the strength of the findings, the drug's developer may seek approval from agencies such as the U.S. Food and Drug Administration or the European Medicines Agency for this specific use. If approved, relacorilant plus nab-paclitaxel could become an additional option for a patient group that currently has few.

Ovarian cancer is often diagnosed at an advanced stage, and platinum-resistant disease remains one of the most challenging frontiers in gynaecologic oncology. Each new late-stage trial result adds a piece to the evidence base that clinicians and patients use to make treatment decisions.

This article reports on a published clinical trial. It does not constitute medical advice. Patients should discuss treatment options with their oncology care team.